TG Therapeutics, Inc. (NASDAQ:TGTX) Q2 2025 Earnings Call Transcript
Operator: Greetings. Welcome to TG Therapeutics' Second Quarter Earnings Call and Webcast. [Operator Instructions] Please note, this conference is being recorded.
Tg Therapeutics Inc. (TGTX)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Persistent Asset Partners Xin Huang | 85,580 | $3,080,024 | +138% | 2.28% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $10.13 | 100,000 | $1,013,000.00 | 12,073,021 | 2023-08-11 | Filing | |
| $10.64 | 9,000 | $95,760.00 | 201,848 | 2023-01-06 | Filing | |
| $7.04 | 50,000 | $351,750.00 | 12,878,185 | 2019-06-26 | Filing | |
| $6.53 | 114,855 | $750,003.15 | 5,114,855 | 2015-02-17 | Filing | |
| $3.43 | 10,000 | $34,300.00 | 7,839,471 | 2013-12-11 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $36.94 | 10,000 | $369,400.00 | 228,816 | 2025-06-13 | Filing | |
| $28.53 | 10,021 | $285,939.21 | 660,611 | 2025-01-06 | Filing | |
| $30.29 | 11,337 | $343,443.08 | 670,632 | 2025-01-03 | Filing | |
| $30.44 | 5,000 | $152,200.00 | 100,195 | 2024-11-11 | Filing | |
| $30.20 | 25,000 | $754,875.00 | 212,479 | 2024-11-11 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 3,490,457 | $126,032,640 | 0.01% | |
| 2. | 906,475 | $32,624,042 | 0.01% | |
| 3. | 796,674 | $28,672,296 | 0.02% | |
| 4. | 525,244 | $18,903,531 | 0.01% | |
| 5. | 190,697 | $6,874,412 | 0.2% |
News See All
TG Therapeutics (TGTX) Slashes 18% on Lower 2025 Sales Guidance
In a statement, TG Therapeutics, Inc. (NASDAQ:TGTX) raised its revenue outlook for Briumvi to a range of $570 million to $575 million from the $560 million previously, but was still lower than the $596...
14 Stocks Jim Cramer Recently Looked At
“Who is powering this market higher?... I think it's the young people, people who are part of the great wealth transfer... They have the money now, and they invest differently from the older folks.
10 Best Cancer Stocks to Invest in for Long-Term Gains
After cardiovascular disease, cancer is the second most common cause of mortality worldwide.
TG Therapeutics, Inc. (NASDAQ:TGTX) Q1 2025 Earnings Call Transcript
Operator: Greetings, and welcome to TG Therapeutics First Quarter Conference Call and Webcast. At this time, all participants are in a listen-only mode.
10 Best Short Squeeze Stocks to Buy According to Analysts
Stock market trading has an ever-changing environment. Short squeeze is among the few phenomena capable of capturing and holding the attention of such markets.
10 Best Performing Growth Stocks in 2025
Heavy AI investments and the tariffs uncertainty have been putting pressure on the technology and growth sector.
TG Therapeutics, Inc. (NASDAQ:TGTX) Q4 2024 Earnings Call Transcript
Operator: Greetings, and welcome to the TG Therapeutics' Fourth Quarter and Full Year Conference Call and Webcast. At this time, all participants are in a listen-only mode.
12 Hot Stocks to Buy According to Analysts
While the stock market in the United States remained closed on January 20 for Martin Luther King, Jr. Day, the day was happening with Donald Trump's inauguration on the same date.
Why TGTX Stock Is Rallying Today
The company estimated today that its 2024 revenue from the MS treatment had come in at $310 million.